BioKangtai(SZ:300601) Xin Lang Cai Jing·2025-09-01 02:15Core Viewpoint - 康泰生物's stock has shown fluctuations in recent trading sessions, with a notable increase in the year-to-date performance, while facing a decline in the short term [1][2]. Financial Performance - As of June 30, 康泰生物 reported a revenue of 1.392 billion yuan for the first half of 2025, representing a year-on-year growth of 15.81% [2]. - The net profit attributable to shareholders for the same period was 37.53 million yuan, which reflects a significant decrease of 77.30% compared to the previous year [2]. Stock Market Activity - On September 1, 康泰生物's stock price increased by 2.03%, reaching 19.09 yuan per share, with a trading volume of 74.48 million yuan and a turnover rate of 0.44% [1]. - The stock has experienced an 11.90% increase year-to-date, a 4.55% decline over the last five trading days, a 7.13% increase over the last 20 days, and a 25.84% increase over the last 60 days [1]. Shareholder Information - As of June 30, 康泰生物 had 61,500 shareholders, a decrease of 1.84% from the previous period, with an average of 14,634 circulating shares per shareholder, which is an increase of 3.48% [2][3]. - The company has distributed a total of 1.765 billion yuan in dividends since its A-share listing, with 525 million yuan distributed over the last three years [3]. Institutional Holdings - As of June 30, the top ten circulating shareholders of 康泰生物 include 易方达创业板ETF, which holds 15.42 million shares, a decrease of 286,200 shares from the previous period [3]. - Other notable shareholders include 招商国证生物医药指数A and 南方中证500ETF, with respective holdings of 10.38 million shares and 9.96 million shares, showing changes in their positions [3].